About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Reducing Infectious Diarrhea in Organ Transplant and Leukemia Patients

by Pooja Shete on December 10, 2020 at 1:00 PM
Font : A-A+

Reducing Infectious Diarrhea in Organ Transplant and Leukemia Patients

The most common form of infectious diarrhea in hospitalized patients is caused by bacteria Clostridium difficile. Clostridium difficile infection (CDI) results in inflammation of the colon.

The most vulnerable population to develop CDI are those patients undergoing blood and bone marrow transplant (BMT) due to their prolonged hospitalization and previous exposure to antimicrobials.

Advertisement


The members of the Hematologic Malignancies Program at Rutgers Cancer Institute of New Jersey examined the use of a low dose of oral vancomycin. At higher dose, vancomycin is used to treat CDI and it is the first and only intervention that decreased CDI rates in a five-year period.

The results were presented at the American Society of Hematology Annual Meeting. The senior author of the study is Dennis Cooper, MD chief of Blood and Marrow Transplantation at Rutgers Cancer Institute and professor of medicine at Rutgers Robert Wood Johnson Medical School.
Advertisement

Infectious diarrhea caused by clostridium difficile has important implications for patients like morbidity and mortality, cost of therapy, and length of stay.

BMT patients are at a greater risk of Clostridium difficile infections as they have a weak immune system. They also take have to medications that place them at a greater risk for infection.

To reduce the risk of CDI in these patients, a simple and less expensive approach of administering oral vancomycin prophylactically was initiated in December 2019. No side effects were seen after the drug administration.

83 percent decrease of CDI was observed in the blood bone marrow transplant and leukemia population within the first eleven months of therapy. This is the first and only intervention that has helped to decrease the CDI rates in cancer in five years, however more time is needed to evaluate the effects of this approach.

At present, all transplant patients are given prophylactic oral vancomycin. Based on these findings, the prevention strategy with vancomycin can also be given to leukemia and solid organ transplant patients in other hospitals and institutes.

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Prevent Hacking of Medical Devices: FDA Sounds Alarm
Black Water: Benefits and Uses
World Hypertension Day 2022 - Measure Blood Pressure Accurately, Control It, Live Longer!
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Tongue Abnormalities Cholera Leukemia Chronic Myeloid Leukemia Acute Myeloid Leukemia Amoebic Dysentery Colo-rectal cancer - Management Acute Lymphoblastic Leukemia Crohns Disease Multiple Myeloma 

Most Popular on Medindia

Accident and Trauma Care Blood Pressure Calculator Blood Donation - Recipients Hearing Loss Calculator Color Blindness Calculator Noscaphene (Noscapine) Calculate Ideal Weight for Infants Pregnancy Confirmation Calculator A-Z Drug Brands in India Selfie Addiction Calculator

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use